Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
11,879 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Global disparities in access to randomized controlled trials for pulmonary arterial hypertension.
Khan D, Matusov Y. · Respir Med · 2026 · cited 0 timessystematic review
- Stem cells, extracellular vesicles, and cell-free strategies in pulmonary arterial hypertension: a bibliometric study, 2006-2026.
Xue X, Zhang H, Cao Y, Wang Z, Song Q, Han J, Wang D, Wu Y, Liu Q. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- HIV-associated pulmonary arterial hypertension: improving survival despite persistent treatment gaps - a systematic review and meta-analysis.
Fernandes Garcia MV, Lahm T. · AIDS · 2026 · cited 0 timesmeta-analysis, systematic review
- Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial.
Ersbøll MK, Kjærgaard J, Waidtløw K, Køber L, Gustafsson F, Kiely DG, Montani D, Carlsen J, Rossing K. · J Heart Lung Transplant · 2026 · cited 1 timesrandomized controlled trial
- Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension.
Yoshida K, Toth E, Duijvelaar E, Neep B, Agarwal S, Pan X, Sanada T, Yoshida Y, Aman J, de Jesus Perez VA, Handoko ML, de Man FS, Sun XQ, Bogaard HJ. · J Am Heart Assoc · 2026 · cited 1 timesclinical trial, phase ii, research support, non-u.s. gov't
- Prognostic value of TAPSE/sPAP in pulmonary arterial hypertension: a systematic review and meta-analysis.
Luo Q, Li S, Huang Z, Ran Y, Zhao Q, Deng L, Zhao Z, Liu Z. · Respir Med · 2026 · cited 1 timesmeta-analysis, systematic review
- Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension.
Hill NS, Gillies H, Chakinala MM, Feldman JP, Hoeper MM, Jing ZC, Mclaughlin VV, Rosenkranz S, Escribano-Subias P, Ghio S, Gomberg-Maitland M, Habib N, Kopec G, Langleben D, Lescano A, Ramirez A, Rischard F, Sitbon O, Skride A, Dake BT, Khindri S, Langley J, Niven R, Zhang X, Humbert M. · Am J Respir Crit Care Med · 2026 · cited 3 timesclinical trial, phase ii, multicenter study
- Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
Carmona-Segovia AD, Morales-Asencio JM, Escribano-Subías P, Rodríguez-Capitán J, Jiménez-Navarro M, Becerra-Muñoz VM. · Health Qual Life Outcomes · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial.
Lachant DJ, Sahay S, Block R, Ossip D, Denning J, Lazarus HM, Parsley E, White RJ. · Ann Am Thorac Soc · 2026 · cited 2 timesclinical trial, phase ii, multicenter study
- Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
McLaughlin VV, Solum D, Lachant D, Ataya A, Barberà JA, Meyer GB, Chang SA, Channick R, Church C, Feenstra J, Gaine S, Giannakoulas G, Jerjes-Sanchez C, Khanna D, Kim NH, Oudiz R, Preston IR, Sood N, Torres F, Vachiery JL, Pulido T, Cella D, Deng C, Escudero M, Lacasse V, Peterson L, Benza R, Humbert M, ADVANCE OUTCOMES Investigators. · Lancet · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial.
Berger RMF, Dunbar Ivy D, Borissoff JI, Cerovic S, Csonka D, Remeňová T, Richard D, Villeneuve M, Beghetti M. · J Pediatr · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial.
Zhou YP, Qiu LH, Ma W, Cao YS, Li J, Huang W, Wang L, Wang DW, Duan HQ, Wang Z, Jiang X, Xu XQ, Ma WG, Huo Y, Jing ZC. · Signal Transduct Target Ther · 2026 · cited 0 timesOpen accessclinical trial, phase ii, randomized controlled trial
- Effects of riociguat on right ventricular size and function in pulmonary arterial hypertension (RIVER II): a prospective, phase IV study.
Harutyunova S, Heinz J, Benjamin N, Brückner L, Sehic F, Egenlauf B, Cittadini A, Marra AM, Grünig E, Xanthouli P. · Respir Res · 2026 · cited 0 timesOpen accessclinical trial, phase iv
- Pulmonary Arterial Hypertension-Targeted Therapy for Pulmonary Hypertension Associated With Left Heart Disease: Bayesian and Frequentist Meta-Analysis of Randomized Controlled Trials.
Kiyohara Y, Sakai T, Freeman LM, Katzianer D, Siuba MT, Chaisson N, Correa A, Trivieri MG, Tang WHW, Yano Y, Naito T, Miyashita S. · Am J Cardiol · 2026 · cited 1 timesmeta-analysis
- Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variant.
Skaug B, Rodolfi S, Denton CP, Shah AA, Choi BN, Gonzalez N, Herrera MA, Martin J, Charles J, Murthy VL, Zhang M, Mayes MD, Assassi S. · Ann Rheum Dis · 2026 · cited 1 timesmeta-analysis
- Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit.
Reddy YNV, Frantz RP, Miranda WR, Harada T, Kazui S, Borlaug BA. · J Am Coll Cardiol · 2026 · cited 12 timesclinical trial, phase iv
- Perioperative management of pulmonary arterial hypertension in children undergoing congenital heart surgery: a systematic review and meta-analysis.
Ikwuanusi E, Rajah T, Scandrett K, Asamane EA, Volpi S. · J Cardiothorac Surg · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Parenteral treprostinil in paediatric pulmonary arterial hypertension: a systematic review and meta-analysis.
Wacker J, Joye R, Beghetti M. · Eur Respir Rev · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Meta-analysis of differential gene expression in idiopathic pulmonary arterial hypertension.
Huang AP, Voskamp S, Ebadi AA, Liedel JL, Nelson JS, Kuruvilla J. · Cardiovasc Pathol · 2026 · cited 0 timesmeta-analysis
- Daily Physical Activity in Pulmonary Arterial Hypertension: Insights From a Multicenter Longitudinal Trial Using Accelerometry.
Minhas J, Shou H, Al-Naamani N, Feng R, Zamanian R, Bull T, Chakinala M, Hemnes A, Moutchia J, Mathai SC, Ellenberg S, Ventetuolo C, Kawut SM. · Chest · 2026 · cited 1 timesmulticenter study, randomized controlled trial
- Efficacy and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials.
Mantoo MR, Majeed MW, Roy A. · Indian Heart J · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Kopeć G, Meyer G, Olsson KM, Fu W, Shi Y, Miller B, Kim SS, Mackenzie HS, Brambatti M, Patel MJ, Koglin J, Cornell AG, Humbert M, HYPERION Trial Investigators. · N Engl J Med · 2025 · cited 36 timesclinical trial, phase iii, multicenter study
- Pulmonary arterial hypertension increases the risk of female sexual dysfunction: a systematic review and meta-analysis.
Qiao X, Su D, Qin S, Shang L, Luo L, Pang Y. · J Sex Med · 2026 · cited 0 timesmeta-analysis, research support, non-u.s. gov't
- Effects of a Sea-Level Stay on Pulmonary Hemodynamics in Patients With Pulmonary Arterial Hypertension Living in Quito Near 2,850 m.
Ulrich S, Müller J, Furian M, Saxer S, Schneider SR, Herzig J, Bauer M, Schmucki M, Saragoni D, Mayer L, Schwarz EI, Cajamarca E, Hoyos R, Lichtblau M. · Chest · 2026 · cited 1 timesclinical trial
- Efficacy of fasudil in COPD-associated pulmonary arterial hypertension: meta-analysis of randomized controlled trials.
Shu P, Xu G, Liu Y, Qu NN. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.